Instalab
logoInstalab

ApoB

Blood Test
A cleaner count of artery-damaging particles, especially when LDL cholesterol looks falsely reassuring.
4.8 (2,719 reviews)
Tested by Quest, Access Medical or Boston Heart
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers · 8-hour fast required
Get results
Explained with clear next steps, no medical jargon

Should you take a ApoB test?

This test is most useful if any of these apply to you.

Healthy but Staying Ahead
Your standard panel looks fine, but you want a cleaner read on ApoB particle burden than LDL cholesterol alone gives.
Living With Diabetes or Insulin Resistance
Diabetes or insulin resistance can hide high ApoB behind acceptable LDL cholesterol.
Worried by Early Heart Disease in Your Family
Early heart disease in relatives makes particle burden and Lp(a) worth checking directly.
Already Taking a Statin
Your LDL may be down, but ApoB shows whether particle burden is still higher than expected.

About ApoB

Two people can walk in with identical cholesterol numbers and leave with very different odds of a heart attack. What often separates them is how many ApoB-carrying particles are in their blood. This test tracks that count.

That count is the clearest lipid signal of whether particles are available to enter artery walls, the process behind most heart attacks and many strokes. It can catch risk that a standard cholesterol panel misses.

What This Test Counts

The marker is ApoB (apolipoprotein B), measured from a blood sample. LDL, VLDL, IDL, lipoprotein(a), and chylomicron remnants each carry one ApoB molecule. Most ApoB in a routine result is ApoB-100 from liver-made particles. A smaller share is ApoB-48 from intestine-made particles, and routine assays do not separate the two.

So your ApoB level is a close headcount of artery-damaging particles, not a measure of how much cholesterol is riding inside them. A standard LDL cholesterol result tells you the cholesterol packed into LDL particles. It does not tell you how many particles are doing the packing.

Heart Attack and Stroke Risk

Across genetic studies, large cohorts, and treatment trials, ApoB tracks future heart attacks more tightly than cholesterol content does.

Who Was StudiedWhat Was ComparedWhat They Found
About 430,000 adults, with and without existing heart diseaseApoB versus cholesterol content and particle typeApoB was the best independent lipid predictor of heart attack
About 207,000 adults without known atherosclerosis, diabetes, or lipid-lowering therapyApoB particle count versus particle type and sizeA higher count meant about a third more coronary artery disease
About 184,000 people in a coronary disease genetics datasetInherited differences linked to ApoB, LDL cholesterol, and triglyceridesApoB carried the main lipid-related genetic signal for coronary risk

Source: Marston et al. (JAMA Cardiology, 2021); Morze et al. (European Heart Journal, 2025); Richardson et al. (PLoS Medicine, 2020).

What this means for you: when ApoB and cholesterol numbers point in different directions, ApoB is usually the better lipid signal. If it is high, the particles it counts are worth bringing down, even if LDL cholesterol looks acceptable.

When Your Standard Panel Looks Reassuring

An LDL cholesterol result can look reassuring while ApoB tells a different story. In one analysis of people with very low LDL cholesterol, about 40% had ApoB that was higher than their LDL cholesterol suggested. They had more particles than the LDL number implied.

This gap shows up most in people with high triglycerides, diabetes, extra weight, or insulin resistance, where particles tend to be small and cholesterol-poor. In one Korean adult screening study, adding ApoB to routine lipid criteria raised the share flagged with a lipid problem from about 27% to about 45%, and roughly 1 in 6 had high ApoB while routine cholesterol looked reassuring.

Diabetes and Metabolic Risk

If you have type 2 diabetes or insulin resistance, LDL cholesterol can look fine while particle count runs high. In one UK Biobank cohort of people with type 2 diabetes, higher ApoB was linked to more cardiovascular events. Excess ApoB sharpened that risk picture further. Excess ApoB compares your measured ApoB with what would be expected from LDL cholesterol alone.

A similar pattern shows up in fatty liver disease. In one observational study of children and teens with obesity, those in the top few percent of ApoB had nearly five times the odds of metabolic fatty liver disease compared with those in the middle of the range.

The Mortality Picture Is More Tangled

Higher ApoB reliably predicts more heart attacks, but its link to overall death is messier. In some studies of people who already have advanced coronary disease, lower ApoB was paired with higher death rates, which sounds backwards.

That pattern is mostly a warning about the people being studied. In advanced coronary disease, low ApoB can travel with malnutrition, liver trouble, and other illness. Those things raise death rates and can also lower cholesterol-carrying proteins. In prevention screening, the practical read is simpler: more ApoB particles means more cardiovascular risk. Genetic evidence backs that up: people who inherit higher ApoB develop more coronary disease, not less, so the backwards pattern in already-sick patients reflects their illness rather than any protection from having fewer particles. ApoB is a marker of particle burden, not a standalone predictor of when you will die.

Why One Reading Is Not the Whole Story

ApoB is a stable, well-standardized blood measurement with relatively little day-to-day fluctuation, which makes it well suited to tracking over time. A single value tells you where you stand today. A trend tells you whether your risk is drifting up as you age or coming down in response to what you are doing about it.

Use repeat testing when you change something that should lower ApoB, such as diet, weight, or lipid-lowering medication. The trend tells you whether the plan moved the particle burden.

What to Do With an Out-of-Pattern Result

The most useful readings are the discordant ones, where ApoB and cholesterol disagree. If ApoB is high while LDL looks fine, treat ApoB as the truer lipid signal and look at what is driving it: check triglycerides, fasting glucose, HbA1c, and blood pressure for a metabolic pattern. HbA1c shows your average blood sugar over the past few months. Measure lipoprotein(a) at least once, since those particles carry ApoB too but add their own inherited risk.

hs-CRP is a blood test for low-grade inflammation. Pairing it with ApoB can help separate particle burden from inflammatory risk, since both can push plaque forward through different routes. If ApoB stays high despite lifestyle changes, or you have a family history of early heart disease, use the full pattern to decide whether lifestyle alone is enough or prescription lipid-lowering makes sense. If the pattern is extreme or hard to explain, a lipid specialist can help.

When a Single Reading Can Mislead

ApoB is more reliable than a calculated LDL cholesterol, and unlike that calculation it does not require fasting. A recent meal should not distort it. Still, a few things can make one reading unrepresentative of your usual level.

  • Acute illness or infection: serious infections and other acute illness can temporarily lower cholesterol-carrying proteins for weeks, so a value drawn while you are sick may read lower than usual.
  • A recent medication change: starting or stopping a lipid-lowering drug shifts ApoB within weeks, so time your test to the question you are actually asking.
  • Lab method: results come from standardized automated assays, but comparing values is cleanest when successive tests use the same lab and method.

What Moves This Biomarker

Evidence-backed interventions that affect your ApoB level

Decrease
Take a statin
Statins are first-line treatment when ApoB is high enough to justify medication. They lower ApoB by prompting the liver to pull more ApoB particles out of blood. Across statin trials, ApoB lowering through this route tracked with fewer heart attacks and strokes.
MedicationStrong Evidence
Decrease
Add a PCSK9 inhibitor to a statin
When a statin alone does not bring particle count low enough, adding one of these injectable drugs pushes ApoB down much further. In a trial after acute coronary syndrome, people who reached the lowest ApoB on alirocumab had the lowest risk of further heart events, even after accounting for achieved LDL cholesterol.
MedicationStrong Evidence
Decrease
Use tirzepatide in type 2 diabetes
In a randomized trial in type 2 diabetes, tirzepatide lowered ApoB and reduced large triglyceride-rich particles. That makes the lipid pattern less particle-heavy while the drug also lowers glucose and weight.
MedicationModerate Evidence
Decrease
Treat true hypothyroidism with thyroid hormone replacement
An underactive thyroid raises ApoB by slowing how fast the liver clears these particles. In people given thyroid hormone replacement, ApoB fell along with cholesterol as normal clearance was restored. This applies only if thyroid function is genuinely low.
MedicationModerate Evidence
Decrease
Replace saturated fat with unsaturated fats or plant protein
Controlled feeding trials measuring plasma ApoB show that ApoB falls when people move from a typical higher-saturated-fat diet toward diets lower in saturated fat or richer in unsaturated fats and plant protein. The drop is usually modest, but it is a real change in the particle burden this test tracks.
NutritionModest Evidence
Decrease
Add ezetimibe to lipid-lowering therapy
Ezetimibe lowers ApoB by reducing cholesterol absorption in the gut. In outcome trials and meta-analyses, therapies that lower ApoB through LDL-receptor pathways, including ezetimibe with statins, reduce cardiovascular events.
MedicationModest Evidence

Frequently Asked Questions

References

26 studies
  1. Marston N, Giugliano R, Melloni G, Park JG, Morrill V, Blazing M, Ference B, Stein E, Stroes E, Braunwald E, Ellinor P, Lubitz S, Ruff C, Sabatine MJAMA Cardiology2021
  2. Morze J, Melloni G, Wittenbecher C, Ala-korpela M, Rynkiewicz a, Guasch-ferre M, Ruff C, Hu F, Sabatine M, Marston NEuropean Heart Journal2025
  3. Sniderman a, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJEuropean Heart Journal2024